Related Experiment Video
Updated: Jun 22, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
'Marginal medicine': targeting comparative effectiveness research to reduce waste
Ari Hoffman1, Steven D Pearson
1Massachusetts General Hospital Institute for Technology Assessment in Boston, Massachusetts, USA.
Health Affairs (Project Hope)
|June 27, 2009
Summary
Comparative effectiveness research aims to reduce healthcare waste by guiding treatment choices. This study introduces a framework for "marginal medicine" to help align research findings with value improvement efforts.
Area of Science:
- Health Services Research
- Health Economics
- Clinical Decision-Making
Background:
- Policymakers anticipate comparative effectiveness research (CER) will reduce U.S. healthcare waste.
- Guidance on optimal health care options for diverse patients is a key goal of CER.
- The precise mechanisms by which CER identifies and reduces waste remain unclear.
Purpose of the Study:
- To present a conceptual framework for categorizing
Main Methods:
- Conceptual framework development.
- Analysis of evidentiary categories for marginal medicine.
- Alignment of CER with healthcare value improvement.
Main Results:
- A framework is proposed to categorize marginal medicine based on evidence.
- This framework can assist in identifying healthcare services with low value.
- The framework aims to bridge CER findings with waste reduction strategies.
Conclusions:
- The proposed framework offers a structured approach to understanding marginal medicine.
- It facilitates the application of CER findings to enhance healthcare value.
- This conceptual tool supports clinicians, researchers, and policymakers in waste reduction efforts.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.